Trial Profile
Phase I Study of a Bruton's Tyrosine Kinase (BTK) Inhibitor in Patients With Rheumatoid Arthritis
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 10 Jul 2014
Price :
$35
*
At a glance
- Drugs Agammaglobulinaemia tyrosine kinase inhibitors (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; First in man
- Sponsors Pharmacyclics
- 10 Jul 2014 New trial record
- 02 May 2014 According to the Pharmacyclics media release, first patient was dosed in this trial during the first quarter of 2014.